The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Once again, Dupixent finished in second place with an impressions SOV of 5.40% and 2.8 billion impressions. Notably, the ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

“After working with my dermatologist, she recommended I start Dupixent, a treatment for people ages 6 months and older with uncontrolled moderate-to-severe eczema.” Dupixent, known clinically ...

clinicians are less likely to prescribe biologics that have not been specifically FDA approved for the treatment of atopic dermatitis. Dupixent and Adbry are FDA approved only for the atopic ...

changing its mind in guidance for the multiple sclerosis and eczema drugs. NICE had previously rejected Roche's Ocrevus (ocrelizumab) for multiple sclerosis and Sanofi's Dupixent (dupilumab) ...

Dementia treatment is more than just medication. It can include lifestyle changes, multimodal therapy, and environmental management, as well. Your dementia treatment plan will depend on underlying ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...